共 50 条
Recent advances in developing targeted protein degraders
被引:0
作者:
Cheng, Binbin
[1
,2
]
Li, Hongqiao
[3
]
Peng, Xiaopeng
[4
]
Chen, Jianjun
[5
]
Shao, Chuxiao
[2
]
Kong, Zhihua
[6
]
机构:
[1] Hubei Polytech Univ, Hubei Key Lab Kidney Dis Pathogenesis & Intervent, Huangshi 435003, Peoples R China
[2] Wenzhou Med Univ, Lishui Peoples Hosp, Cent Lab, Lishui Hosp, Lishui 323000, Zhejiang, Peoples R China
[3] Cent Hosp Huangshi, Huangshi 435000, Peoples R China
[4] Gannan Med Univ, Coll Pharm, Ganzhou 314000, Peoples R China
[5] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, NMPA Key Lab Res & Evaluat Drug Metab, Guangzhou 510515, Peoples R China
[6] Guangdong Prov Hosp, Integrated Tradit Chinese & Western Med, Foshan 528200, Peoples R China
基金:
中国国家自然科学基金;
关键词:
Targeted protein degradation;
Small molecule ligands;
PROTACs;
Molecular glues;
LYTACs;
HyTTD;
ANTIBODY-BASED PROTACS;
MDM2;
INHIBITORS;
CANCER-THERAPY;
DEGRADATION;
DISCOVERY;
LIGASE;
ASGPR;
POTENT;
D O I:
10.1016/j.ejmech.2024.117212
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Targeted protein degradation (TPD) represents a promising therapeutic approach, encompassing several innovative strategies, including but not limited to proteolysis targeting chimeras (PROTACs), molecular glues, hydrophobic tag tethering degraders (HyTTD), and lysosome-targeted chimeras (LYTACs). Central to TPD are small molecule ligands, which play a critical role in mediating the degradation of target proteins. This review summarizes the current landscape of small molecule ligands for TPD molecules. These small molecule ligands can utilize the proteasome, lysosome, autophagy, or hydrophobic-tagging system to achieve the degradation of target proteins. The article mainly focuses on introducing their design principles, application advantages, and potential limitations. A brief discussion on the development prospects and future directions of TPD technology was also provided.
引用
收藏
页数:19
相关论文
共 50 条